Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ATXS Stock Forecast 2026-2027
$12.58
Current Price
$718.13M
Market Cap
Buy 0
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to ATXS Price Targets
+3.3%
To High Target of $13.00
+3.3%
To Median Target of $13.00
+3.3%
To Low Target of $13.00
ATXS Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+110.7%
1 Year Change
-3.9%
Year-to-Date Change
-5.3%
From 52W High of $13.29
+253.9%
From 52W Low of $3.56
📊 TOP ANALYST CALLS
Did ATXS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Astria is one of their latest high-conviction picks.
Latest ATXS Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, ATXS has a neutral consensus with a median price target of $13.00 (ranging from $13.00 to $13.00). The overall analyst rating is Buy (6.0/10). Currently trading at $12.58, the median forecast implies a 3.3% upside. This outlook is supported by 0 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Laura Chico at Wedbush, projecting a 3.3% upside. Conversely, the most conservative target is provided by Laura Chico at Wedbush, suggesting a 3.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATXS Analyst Ratings
0
Buy
4
Hold
0
Sell
ATXS Price Target Range
Low
$13.00
Average
$13.00
High
$13.00
Current: $12.58
Latest ATXS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATXS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 12, 2025 | Cantor Fitzgerald | Steven Seedhouse | Neutral | Downgrade | $N/A |
| Oct 16, 2025 | HC Wainwright & Co. | Joseph Pantginis | Neutral | Downgrade | $N/A |
| Oct 15, 2025 | JMP Securities | Jonathan Wolleben | Market Perform | Downgrade | $N/A |
| Oct 15, 2025 | Wedbush | Laura Chico | Neutral | Downgrade | $13.00 |
| Oct 14, 2025 | Jefferies | Eun Yang | Hold | Downgrade | $13.00 |
| Sep 17, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $20.00 |
| Sep 17, 2025 | Cantor Fitzgerald | Steven Seedhouse | Overweight | Reiterates | $49.00 |
| Aug 13, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Aug 13, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $26.00 |
| Jun 13, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| May 14, 2025 | Cantor Fitzgerald | Timur Ivannikov | Overweight | Reiterates | $47.00 |
| Apr 29, 2025 | Cantor Fitzgerald | Steven Seedhouse | Overweight | Initiates | $47.00 |
| Mar 12, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $28.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Mar 3, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $26.00 |
| Feb 27, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jan 31, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Initiates | $26.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $N/A |
Astria Therapeutics Inc. (ATXS) Competitors
The following stocks are similar to Astria based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Astria Therapeutics Inc. (ATXS) Financial Data
Astria Therapeutics Inc. has a market capitalization of $718.13M with a P/E ratio of -7.5x. The company generates $706,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -4,830.6% and return on equity of -43.1%.
Valuation Metrics
Market Cap
$718.13M
Enterprise Value
$590.19M
P/E Ratio
-7.5x
PEG Ratio
-0.2x
Price/Sales
1,017.2x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-4,830.6%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+31.7%
Current Ratio
10.8x
Debt/Equity
1.9x
ROE
-43.1%
ROA
-26.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Astria Therapeutics Inc. (ATXS) Business Model
About Astria Therapeutics Inc.
What They Do
Develops innovative therapies for rare diseases.
Business Model
Astria Therapeutics Inc. generates revenue by advancing its biopharmaceutical products through clinical trials and ultimately bringing new therapies to market for rare and niche diseases. By focusing on specific unmet medical needs, particularly in conditions like hereditary angioedema, the company aims to create impactful solutions that improve patient outcomes.
Additional Information
The company is committed to leveraging cutting-edge research and science-driven approaches to enhance its product pipeline. Its work is particularly significant within the biotechnology and healthcare sectors, aiming to transform the standard of care for underserved medical communities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
78
CEO
Ms. Jill C. Milne Ph.D.
Country
United States
IPO Year
2015
Website
www.astriatx.comAstria Therapeutics Inc. (ATXS) Latest News & Analysis
Latest News
Quick Summary
Astria Therapeutics' stockholders approved its acquisition by BioCryst Pharmaceuticals, expected to close around January 23, 2026, pending customary conditions.
Why It Matters
The approval of the merger between Astria Therapeutics and BioCryst Pharmaceuticals could impact stock prices, market positioning, and future growth prospects for both companies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Astria Therapeutics holds a $13 target price with a 'hold' rating amid Biocryst's acquisition plans, expected to close by Q1 2026. The focus shifts to merger arbitrage with minimal barriers.
Why It Matters
The shift to merger arbitrage signals potential profitability for investors, with a high probability of deal closure enhancing the attractiveness of Astria Therapeutics shares amid reduced risks.
Source: Seeking Alpha
Market Sentiment:
Positive
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
8 months ago
Quick Summary
Astria Therapeutics (NASDAQ: ATXS) reported Q3 2025 financial results and highlighted a proposed transaction with BioCryst to advance its therapy navenibart for HAE treatment.
Why It Matters
Astria Therapeutics' potential transaction with BioCryst may enhance its drug development pipeline, impacting future revenues and market position in treating HAE, influencing investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Astria Therapeutics (ATXS) reported a quarterly loss of $0.55 per share, worse than the expected loss of $0.41, and compared to a loss of $0.42 per share from the previous year.
Why It Matters
Astria Therapeutics' larger-than-expected quarterly loss may signal financial distress, impacting investor confidence and potentially leading to stock price declines.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Astria Therapeutics (NASDAQ:ATXS) reported positive results from its ALPHA-STAR Phase 1b/2 trial of navenibart for hereditary angioedema, involving 29 patients across 20 sites in six countries.
Why It Matters
Positive trial results for navenibart could enhance Astria Therapeutics' market position and attract investment, signaling potential revenue growth and advancements in treatment for HAE.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Astria Therapeutics, Inc. (Nasdaq:ATXS) will present final results from the ALPHA-STAR trial of navenibart for hereditary angioedema at the ACAAI Annual Meeting on November 6-10, 2025.
Why It Matters
The announcement of final trial results for navenibart could significantly impact Astria Therapeutics' stock price and future funding, influencing investor sentiment and potential market performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ATXS Stock
What is Astria Therapeutics Inc.'s (ATXS) stock forecast for 2027?
Based on our analysis of 10 Wall Street analysts, Astria Therapeutics Inc. (ATXS) has a median price target of $13.00. The highest price target is $13.00 and the lowest is $13.00.
Is ATXS stock a good investment in 2027?
According to current analyst ratings, ATXS has 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATXS stock?
Wall Street analysts predict ATXS stock could reach $13.00 in the next 12 months. This represents a 3.3% increase from the current price of $12.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Astria Therapeutics Inc.'s business model?
Astria Therapeutics Inc. generates revenue by advancing its biopharmaceutical products through clinical trials and ultimately bringing new therapies to market for rare and niche diseases. By focusing on specific unmet medical needs, particularly in conditions like hereditary angioedema, the company aims to create impactful solutions that improve patient outcomes.
What is the highest forecasted price for ATXS Astria Therapeutics Inc.?
The highest price target for ATXS is $13.00 from Laura Chico at Wedbush, which represents a 3.3% increase from the current price of $12.58.
What is the lowest forecasted price for ATXS Astria Therapeutics Inc.?
The lowest price target for ATXS is $13.00 from Laura Chico at Wedbush, which represents a 3.3% increase from the current price of $12.58.
What is the overall ATXS consensus from analysts for Astria Therapeutics Inc.?
The overall analyst consensus for ATXS is neutral. Out of 10 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are ATXS stock price projections?
Stock price projections, including those for Astria Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 1:31 AM UTC